 EDISON, N.J., June 09, 2021 GLOBE NEWSWIRE -- Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, Hepion, a clinical stage biopharmaceutical company focused on Artificial Intelligence AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis NASH and liver disease, is pleased to announce that it is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, according to a preliminary list of additions posted June 4. 